Tech News
Back to home
Technology

Here’s the latest company planning for gene-edited babies

Source

MIT Technology Review

Published

TL;DR

AI Generated

A West Coast biotech entrepreneur has secured $30 million to form a company, Preventive, dedicated to researching the safety of creating genetically edited babies through heritable genome editing. The company aims to correct harmful mutations or install beneficial genes in embryos to prevent disease. Despite controversy and legal restrictions on gene-editing humans, Preventive is one of three US startups pursuing this technology. While some in the industry see potential health benefits, critics like gene-editing expert Fyodor Urnov caution against moving forward with heritable genome editing, calling it dangerous and misguided. Preventive's founder, Lucas Harrington, believes that if proven safe, this technology could be revolutionary in healthcare.

Read Full Article

Similar Articles

MIT Technology Review

Exclusive eBook: Inside the stealthy startup that pitched brainless human clones

The exclusive eBook delves into R3 Bio, a startup proposing brainless human clones as backup bodies for longevity. The startup's ethically charged vision raises concerns about cloning ethics. The eBook, available only to subscribers, explores the controversial pursuit of human longevity through cloning. Antonio Regalado's work sheds light on the startup's startling concept and its potential implications.

MIT Technology Review•
Biohacker claims to have sequenced their own genome at the kitchen table with M3 Ultra Mac Studio, Claude, and a $3,200 sequencer — DIY project requires 100GB of data storage per run, oodles of RAM

Biohacker claims to have sequenced their own genome at the kitchen table with M3 Ultra Mac Studio, Claude, and a $3,200 sequencer — DIY project requires 100GB of data storage per run, oodles of RAM

A biohacker claims to have sequenced their own genome at home using a Mac Studio and biotech gadgets like the Oxford Nanopore MinION, costing $3,200. The DIY project requires significant data storage and RAM. Motivated by a family history of autoimmune disease, the individual emphasizes that this kitchen table genome sequencing is not a substitute for clinical diagnosis. The process involved using the MinION sequencer to target specific genes related to the autoimmune disease. The blogger provides detailed information on the equipment used and expenses incurred, welcoming others interested in genome sequencing to reach out for assistance.

Tom's Hardware•
MIT Technology Review

The Download: murderous ‘mirror’ bacteria, and Chinese workers fighting AI doubles

Scientists initially proposed creating mirror bacteria with reversed proteins and sugars for research purposes, but now fear these organisms could pose a catastrophic threat to life on Earth. In China, tech workers are concerned about AI replication of their skills and personalities, leading to fears of losing professional identity. Meanwhile, the White House and Anthropic are working on a compromise, and other tech news includes Palantir's manifesto, Germany's push for looser AI rules, and Nvidia's shift towards AI over gaming.

MIT Technology Review•
MIT Technology Review

What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma

Moderna is facing a dilemma over whether to call its cancer treatment a "vaccine" or a "therapy" to distance itself from vaccine skepticism. The company's mRNA technology is being used in partnership with Merck to develop individualized neoantigen therapy for cancer treatment. Despite the promising results, some are concerned that patients may be misled by the terminology change. Moderna's strategy to rebrand its cancer treatment may be a response to government scrutiny over its mRNA vaccines. The debate over terminology reflects the broader challenges in navigating public perception and regulatory hurdles in the biotech industry.

MIT Technology Review•

We use cookies

We use cookies to ensure you get the best experience on our website. For more information on how we use cookies, please see our cookie policy.